News

Polyphor and EnBiotix to Merge, Plan Trials in 2 Lung Infection Therapies

EnBiotix has purchased murepavadin, an investigational inhaled antibiotic to treat Pseudomonas aeruginosa infections in people with cystic fibrosis (CF), from Polyphor. The two companies also entered into an agreement to merge, wherein Polyphor will acquire all EnBiotix stock in exchange for Polyphor stock newly issued upon closing. The merger…

Study: Use Lung Clearance Index to Measure Function

An assessment called the lung clearance index could be used to help identify people with cystic fibrosis (CF) who are at high risk for worsening lung function, a study has found. The study reported on factors associated with a worsening lung clearance index (LCI) over time in CF patients,…

Kalydeco Approved in Canada to Treat Infants 4 Months and Older

Health Canada has extended the use of Kalydeco (ivacaftor) to treat babies, starting at 4 months old, who have cystic fibrosis (CF) caused by certain mutations. The specific gating mutations covered are: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, and S549R. Kalydeco, Vertex Pharmaceuticals, was previously approved in…

65 Roses Ladies Golf Classic Benefits CF Canada

The Calgary and Southern Alberta Chapter of Cystic Fibrosis Canada has announced that this year’s 65 Roses Ladies Golf Classic, a women-only golf tournament to raise funds and awareness for cystic fibrosis (CF), will take place Sept. 13 at Earl Grey Golf Club in Calgary. The event offers…

Researchers Explore Trikafta in Younger Patients

Researchers at the Children’s Hospital Colorado Breathing Institute are participating in four new studies to evaluate the long-term impact of Trikafta (elexacaftor, tezacaftor, and ivacaftor) in people with cystic fibrosis (CF) ages 6 and older, its effectiveness in infants and children younger than 6, and to find alternative…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.